Altimmune OverviewAltimmune EBIT
EBIT (Earnings Before Interest and Taxes) analysis for ALT.
Quarterly EBIT
-$24.24M
↓ 11.13% YoY
As of Mar 31, 2026
Annual EBIT (TTM)
-$96.95M
↓ 0.41% YoY
Trailing 12 months ending Mar 31, 2026
Altimmune OverviewEBIT (Earnings Before Interest and Taxes) analysis for ALT.
As of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026